Furthermore, the inhibitor (ipilimumab) for cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), which suppresses immune responses, has been approved for treating NSCLC [5] and some other cancers [7]. The gene discussed is CTLA4; the disease is cancer.